Benner, J.S., Smith, T.W., Klingman, D., Tierce, J.C., Mullins, C.D., Pethick, N., et al. (2005) Cost effective-ness of rosuvastatin compared with other statins from a managed care perspective value in health, 8(6), 618-628.

has been cited by the following article:

• TITLE: Considering the cost-effectiveness of statins in family practice in Turkey from a payer perspective

  AUTHORS: Güvenç Koçkaya, Albert Wertheimer, Pınar Daylan Koçkaya, Ahmet Esen

  KEYWORDS: Hypercholesterolemia; Cardiovascular Disease; Cost-Effectiveness Analysis; Decision Analysis Mode

  JOURNAL NAME: Health, Vol.1 No.4, December 29, 2009

  ABSTRACT: The percentage of mortality caused by cardio-vascular events in European Countries and European Union Countries is respectively 49% and 42% of all mortality causes. Our estimates about cardiovascular mortality in Turkey depend on TEKHARF (Hearth Disease and Risk Factors in Turkish Adults) which depended on a 12 year observation. It has been reported that cardio-vascular mortality rates for Turkey in men and women were 0.082% and 0.043% respectively. In Turkey, Atorvastatin, Fluvastatin, Pravastatin, Rosuvastatin and Simvastatin are the different alternatives found in the statin market. All stat-ins are reimbursed by insurance companies. The aim of this study is to determine the cost- effectiveness of statins. In conclusion, simvas-tatin and rosuvastatin comprised the optimal two statin alternatives.